Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00659685
Recruitment Status : Completed
First Posted : April 16, 2008
Last Update Posted : April 16, 2008
Algorithme Pharma Inc
Information provided by:
Par Pharmaceutical, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Primary Completion Date : No date given
Study Completion Date : No date given